Skip to content

Study · Non-randomized trial · n = 45 · 2021

4 results

Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects: an open-label, one-sequence crossover, single-center, multiple-dose, two-part trial.

Hauge C, Breitschaft A, Hartoft-Nielsen ML, Jensen S, Bækdal TA

Expert opinion on drug metabolism & toxicology31 Aug 2021Cited by 23 (Europe PMC)

PMID34289755 (opens in a new tab)DOI10.1080/17425255.2021.1955856 (opens in a new tab)PepBankPUB-34289755
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In healthy subjects, oral semaglutide raised total thyroxine exposure by 33% after levothyroxine versus levothyroxine alone.

    In plain wordsIn healthy people, taking oral semaglutide with levothyroxine raised thyroxine exposure by 33% compared with levothyroxine alone.

    Peptide
    Semaglutide
    Outcome
    IncreaseTotal thyroxine exposure after levothyroxine
    Study

    n = 45

    Comparator
    Levothyroxine alone
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    14 mg once daily at steady state · oralAs given in this study (human).

    Measurements

    Increase in total T4 exposure
    33%
    levothyroxine plus oral semaglutide vs levothyroxine alone

    Source sentences

    Summary
    A 33% increase in total T4 exposure was observed with levothyroxine/oral semaglutide vs levothyroxine alone
    2 context sentences
    Summary · context
    In this one-sequence crossover trial, 45 healthy subjects received levothyroxine (600 μg single-dose) alone, or with concomitant SNAC 300 mg or concomitant oral semaglutide 14 mg at steady-state.
    Summary · context
    Subjects also received oral semaglutide 14 mg at steady-state alone or with five placebo tablets once-daily for 5 weeks.
  2. 02HumanNon-randomized trialPharmacokinetics

    In healthy subjects, baseline-corrected thyroxine Cmax was unaffected by oral semaglutide.

    In plain wordsIn healthy people, oral semaglutide did not change peak thyroxine levels after levothyroxine.

    Peptide
    Semaglutide
    Outcome
    No significant changeBaseline-corrected thyroxine Cmax after levothyroxine
    Study

    n = 45

    Comparator
    Levothyroxine alone
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    14 mg once daily at steady state · oralAs given in this study (human).

    Source sentences

    Summary
    but baseline-corrected maximum concentration (Cmax) was unaffected.
    2 context sentences
    Summary · context
    In this one-sequence crossover trial, 45 healthy subjects received levothyroxine (600 μg single-dose) alone, or with concomitant SNAC 300 mg or concomitant oral semaglutide 14 mg at steady-state.
    Summary · context
    Subjects also received oral semaglutide 14 mg at steady-state alone or with five placebo tablets once-daily for 5 weeks.
  3. 03HumanNon-randomized trialPharmacokinetics

    In healthy subjects, co-administering five placebo tablets decreased semaglutide exposure by 34%.

    In plain wordsIn healthy people, taking five placebo tablets with oral semaglutide lowered semaglutide exposure by 34%.

    Peptide
    Semaglutide
    Outcome
    DecreaseSemaglutide exposure with placebo tablets
    Study

    n = 45

    Comparator
    Oral semaglutide alone
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    14 mg once daily at steady state · oral · 5 weeksAs given in this study (human).

    Measurements

    Decrease in semaglutide exposure
    34%
    oral semaglutide with placebo tablets

    Source sentences

    Summary
    A 34% decrease in semaglutide exposure was observed when oral semaglutide was co-administered with placebo tablets
    2 context sentences
    Summary · context
    In this one-sequence crossover trial, 45 healthy subjects received levothyroxine (600 μg single-dose) alone, or with concomitant SNAC 300 mg or concomitant oral semaglutide 14 mg at steady-state.
    Summary · context
    Subjects also received oral semaglutide 14 mg at steady-state alone or with five placebo tablets once-daily for 5 weeks.
  4. 04HumanNon-randomized trialPharmacokinetics

    In healthy subjects, co-administering five placebo tablets decreased semaglutide Cmax.

    In plain wordsIn healthy people, taking five placebo tablets with oral semaglutide lowered peak semaglutide levels.

    Peptide
    Semaglutide
    Outcome
    DecreaseSemaglutide Cmax with placebo tablets
    Study

    n = 45

    Comparator
    Oral semaglutide alone
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    14 mg once daily at steady state · oral · 5 weeksAs given in this study (human).

    Source sentences

    Summary
    and Cmax also decreased.
    2 context sentences
    Summary · context
    In this one-sequence crossover trial, 45 healthy subjects received levothyroxine (600 μg single-dose) alone, or with concomitant SNAC 300 mg or concomitant oral semaglutide 14 mg at steady-state.
    Summary · context
    Subjects also received oral semaglutide 14 mg at steady-state alone or with five placebo tablets once-daily for 5 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.